Focus: Conception is a Berkeley-based biotechnology company specializing in the conversion of cells into eggs, operating at the intersection of cell therapy and women's health. The company is publicly listed with a focused pipeline in reproductive biology and related therapeutic areas.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Conception presents a high-risk, high-differentiation opportunity suitable only for scientists betting on a transformative cell therapy platform in women's health, but with significant visibility gaps on pipeline, financials, and growth trajectory.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Conception
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Conception's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Vertical Data Inc. (VDTA) (CIK 0002033264) — EX-10.1
EX-10.1
8-K Filing: DarioHealth Corp. (DRIO) (CIK 0001533998) — EXHIBIT 10.2
EXHIBIT 10.2
8-K Filing: Bakkt, Inc. (BKKT, BKKT-WT) (CIK 0001820302) — EX-10.2
EX-10.2
8-K Filing: KAISER ALUMINUM CORP (KALU) (CIK 0000811596) — EX-10.2
EX-10.2
8-K Filing: Skye Bioscience, Inc. (SKYE) (CIK 0001516551) — EX-2.1
EX-2.1
8-K Filing: Star Equity Holdings, Inc. (STRR, STRRP) (CIK 0001210708) — EX-2.1
EX-2.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo